TY - EJOU
AU - Long, Qifang
AU - Zhu, Weipei
AU - Zhou, Jundong
AU - Wu, Jinchang
AU - Lu, Weixian
AU - Zheng, Cui
AU - Zhou, Dongmei
AU - Yu, Ling
AU - Yang, Ru
TI - Truncated Bid Overexpression Induced by Recombinant Adenovirus Cre/LoxP System Suppresses the Tumorigenic Potential of CD133+ Ovarian Cancer Stem Cells
T2 - Oncology Research
PY - 2017
VL - 25
IS - 4
SN - 1555-3906
AB - Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide.
Cancer stem cells (CSCs) have been identified in ovarian cancer and other malignant tumors as a small
population of cells that are capable of self-renewal and multidifferentiation. CD133+
ovarian CSCs have been
reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged
as one of the most promising therapeutic markers for ovarian cancer treatment. In the current study, we constructed a recombinant adenovirus Cre/loxP regulation system to selectively introduce truncated Bid (tBid)
expression specifically targeting CD133+
in ovarian CSCs. The results demonstrated that the coinfection
of Ad-CD133-Cre and Ad-CMV-LoxP-Neo-LoxP-tBid significantly increased tBid expression in CD133+
ovarian CSCs. Moreover, the tBid overexpression induced by a recombinant adenovirus Cre/loxP system
dramatically inhibited cell proliferation and invasion, significantly elevated cell apoptosis, and activated the
mitochondrial apoptosis pathway in CD133+
ovarian CSCs. Additionally, recombinant adenovirus Cre/loxP
system-mediated tBid overexpression suppressed the tumorigenic potential of CD133+
ovarian CSCs in a
xenograft mouse model. In conclusion, our study successfully constructed a recombinant adenovirus Cre/loxP
system and induced tBid overexpression in CD133+
ovarian CSCs, providing a new therapeutic approach for
ovarian cancer treatment.
KW - Truncated Bid (tBid); Cre/loxP system; Ovarian cancer; CD133; Cancer stem cells (CSCs)
DO - 10.3727/096504016X14765492198706